Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Paclitaxel (Primary) ; Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms FREEDOM
- 17 Jan 2017 Results of post hoc secondary analysis published in the Journal of the American College of Cardiology
- 09 Sep 2013 Planned number of patients changed from 2400 to 1900 as reported by ClinicalTrials.gov.
- 08 Apr 2013 Planned End Date changed from 1 Dec 2011 to 1 Dec 2018 as reported by ClinicalTrials.gov.